p21 and p27: The CIP/KIP CDK Inhibitors

Two Families of CDK Inhibitor

Cells have two structurally distinct sets of CDK inhibitors. The INK4 proteins (including p16 from CDKN2A) act only on CDK4 and CDK6. The CIP/KIP proteins, p21 (CDKN1A), p27 (CDKN1B) and p57 (CDKN1C), act more broadly across cyclin E-, A- and B-CDK complexes.

This broader reach means CIP/KIP proteins can arrest the cycle at more than one point.

p21 as a p53 Effector

p21 is a direct transcriptional target of p53. When p53 is stabilised by DNA damage, induced p21 inhibits cyclin E-CDK2 and enforces a G1 arrest, and it also contributes to a durable G2 arrest and to senescence.

Because p21 is downstream of p53, tumours that inactivate p53 lose p21 induction without needing to alter the CDKN1A gene itself.

p27 as a Dose-Dependent Tumour Suppressor

p27 levels are high in quiescent cells and fall when cells are stimulated to divide, largely through SCF-SKP2-mediated degradation. Even a partial reduction in p27 can promote proliferation, making it a haploinsufficient tumour suppressor.

In several cancers p27 is not lost but is exported to the cytoplasm after phosphorylation by AKT, where it cannot inhibit nuclear CDKs and may even promote cell migration.

A Complicating Role in CDK4/6 Complexes

CIP/KIP proteins are not purely inhibitory. At certain concentrations they act as assembly factors that help cyclin D bind CDK4/6, and sequestration of p21 and p27 by cyclin D-CDK4/6 frees cyclin E-CDK2.

This dual behaviour is one reason CIP/KIP biology is harder to summarise than the INK4 proteins, and why simple high-or-low readouts can be misleading.

Interpretation Notes

Low p21 or p27 staining by immunohistochemistry is a common finding in aggressive tumours, but it reflects many possible upstream causes and is not a specific test for any one pathway lesion.

CDKN1B mutations do occur, notably in some neuroendocrine tumours, and should be interpreted with the same care as any other variant.

Key Takeaways

• ·p21 and p27 are broad CDK inhibitors, in contrast to the CDK4/6-specific INK4 proteins.
• ·p21 is a p53 effector; p27 is a dose-sensitive tumour suppressor often mislocalised in cancer.
• ·CIP/KIP proteins also help assemble cyclin D-CDK4/6 complexes, complicating interpretation.
• ·Loss of function is usually through level or location, not mutation.